Combination therapy with Polymyxin B (cas 1404-26-8) for carbapenemase-producing Klebsiella pneumoniae bloodstream infection

Add time:09/07/2019    Source:sciencedirect.com

ABSTRACTKlebsiella pneumoniae carbapenemase-producing K. pneumoniae (KPC-KP) bloodstream infections (BSIs) are related to high mortality rates, and combination therapy has been associated with lower mortality in patients treated mostly with colistin. There is a paucity of studies addressing Polymyxin B (cas 1404-26-8) (PMB) treatment for KPC-KP infections. This was a retrospective cohort study of patients with monomicrobial KPC-KP BSIs. The primary outcome was 30-day mortality. Antimicrobial therapy was defined as empirical (started within the first 48 h) or definitive (initiated after >48 h) and was evaluated as follows: monotherapy (only one in vitro active agent or combination therapy of one in vitro active agent plus one or more in vitro non-active agents); and combination therapy with two or more in vitro active agents. A total of 82 KPC-KP BSIs were included; 40 patients (48.8%) died in the first 30 days. Mortality of patients treated with the combination of two in vitro active antimicrobial agents, mostly PMB plus amikacin, was significantly lower (37.5%) compared with monotherapy (64.7%) (P= 0.01). Combination therapy [adjusted hazard ratio (aHR) = 0.40, 95% confidence interval (CI) 0.22–0.83; P = 0.01] was independently associated with lower 30-day survival when controlled for non-surgical admission (aHR = 2.33, 95% CI 1.14–4.80; P = 0.02) and use of vasoactive drugs (aHR = 7.37, 95% CI 3.01–18.02; P < 0.01). In conclusion, combination therapy with two in vitro active agents, mostly PMB plus amikacin, showed a survival benefit compared with other regimens.

We also recommend Trading Suppliers and Manufacturers of Polymyxin B (cas 1404-26-8). Pls Click Website Link as below: cas 1404-26-8 suppliers

Prev:An alternative strategy for combination therapy: Interactions between Polymyxin B (cas 1404-26-8) and non-antibiotics
Next:Antimicrobial Susceptibility StudiesSynergy of Polymyxin B (cas 1404-26-8), tigecycline and meropenem against carbapenem-resistant Enterobacter cloacae complex isolates)